Review Article

Prospects of HA-Based Universal Influenza Vaccine

Anwar M. Hashem\textsuperscript{1,2}

\textsuperscript{1}Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, P.O. Box 80205, Jeddah 21589, Saudi Arabia

\textsuperscript{2}Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 21589, Jeddah 21589, Saudi Arabia

Correspondence should be addressed to Anwar M. Hashem; amhashem@kau.edu.sa

Received 8 November 2014; Accepted 23 December 2014

Copyright © 2015 Anwar M. Hashem. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Current influenza vaccines afford substantial protection in humans by inducing strain-specific neutralizing antibodies (Abs). Most of these Abs target highly variable immunodominant epitopes in the globular domain of the viral hemagglutinin (HA). Therefore, current vaccines may not be able to induce heterosubtypic immunity against the divergent influenza subtypes. The identification of broadly neutralizing Abs (BnAbs) against influenza HA using recent technological advancements in antibody libraries, hybridoma, and isolation of single Ab-secreting plasma cells has increased the interest in developing a universal influenza vaccine as it could provide life-long protection. While these BnAbs can serve as a source for passive immunotherapy, their identification represents an important step towards the design of such a universal vaccine. This review describes the recent advances and approaches used in the development of universal influenza vaccine based on highly conserved HA regions identified by BnAbs.

1. Introduction

Influenza viruses cause highly contagious respiratory tract infections associated with high morbidity and mortality rates. Complications, hospitalization, and associated death most directly impact young children, individuals with chronic diseases, and the elderly [1]. Each year, seasonal influenza epidemics affect up to 500 million people, causing 3 to 5 million cases of severe illness, death of up to 500,000 people, and debilitating economic costs worldwide [2].

All influenza viruses (A, B, and C) belong to Orthomyxoviridae family. Among these genera, influenza types A and B viruses are associated with severe respiratory infections in humans. Influenza A viruses are categorized into different subtypes based on the surface hemagglutinin (HA) and neuraminidase (NA) glycoproteins. To date, there are at least 18 HA (1–18) and 11 NA (1–11) subtypes including the recently isolated highly divergent influenza A viruses from bats (H17N10 and H18N11 from bats), which serve as a natural reservoir for influenza A viruses [3, 4]. These viruses in wild aquatic birds are usually benign and evolutionarily stable, but they are in continuous evolution in mammalian hosts and land-based poultry [10, 11]. The evolution rate of influenza A viruses in humans differs among the different segments with the surface proteins, especially HA, evolving faster than the internal proteins mostly due to the selective immune pressure imposed by the host’s immune system as well as the structural restrictions on the internal proteins [8]. The gradual accumulation of point mutations in influenza genes especially those encoding HA and NA (antigenic drift), can lead to selection and emergence of novel variant strains which can cause annual epidemics [12]. In addition, antigenically novel strains or subtypes of influenza A virus can emerge and spread rapidly due to a major antigenic change known as antigenic shift, causing global pandemics such as the ones that occurred in the last century or the recent H1N1 pandemic (pdmH1N1) in 2009 [13–18].
Until 1997, only H1N1, H2N2, and H3N2 subtypes circulated in humans with limited cases of direct transmission of avian viruses to humans. It was believed that the differences in receptor specificity between human and avian viruses represent a host range barrier. However, since 1997, direct transmission of the highly pathogenic avian influenza (HPAI) H5N1 virus from poultry to humans has increased and resulted in high mortality rate [19]. Other avian viruses such as H9N2 [20], H7N7 [21], and H7N9 [22] have also been isolated from humans. Although human-to-human transmission of these viruses has been limited so far, the ability of these HPAI viruses to infect humans and cause disease as well as their persistent circulation in domestic poultry have raised the concerns about their potential to cause devastating pandemics.

2. Current Influenza Vaccines

Several vaccination strategies have been evaluated for prevention against influenza; however, inactivated vaccines (i.e., whole inactivated virus, split vaccine, or subunit vaccine) are the most widely used approaches [23]. More recently, live-attenuated influenza vaccine (LAIV) has been approved for use in Russia, Europe, and USA [24–27]. These vaccines are typically trivalent containing two influenza A strains (H1N1 and H3N2) and one influenza B strain [1]. Recently, a quadrivalent influenza vaccine containing two influenza B strains from both Yamagata and Victoria lineages in addition to the two influenza A strains was approved for use in the USA and Europe [27, 28].

These vaccines provide substantial protection by predominantly inducing HA and NA strain-specific neutralizing antibodies (Abs) [29, 30]. LAIV are usually more effective in eliciting broad immune response including mucosal, systemic, and cell-mediated responses compared to inactivated vaccines which are weak in inducing mucosal immunity [31]. Many factors can influence the efficacy of inactivated vaccines including the antigenic match between circulating and vaccine strains, the age of the recipients, and their history of influenza exposure [32]. When the vaccine and circulating viruses are antigenically matched, these inactivated vaccines show 70–90% efficacy in healthy adults aged <65 years. Effectiveness against culture-confirmed influenza illness among children aged >6 months to 18 years varies between 50 and 90% depending on their age. However, it is 20–70% effective in preventing hospitalization in the elderly [1]. On the other hand, LAIV was reported to have up to 93% overall efficacy against culture-confirmed influenza and 86% against a mismatched H3N2 strain [31–33]. LAIV was shown to be more protective than inactivated vaccines in children 6 months to 18 years of age [32]. Both vaccines have similar efficacy in individuals between 17 and 49 years of age [1]. However, in the elderly, both vaccines have reduced immunogenicity and efficacy. Thus, a combination of both might be required to increase vaccine efficacy [32].

3. Drawbacks of Current Influenza Vaccines

The high antigenic variability of HA and NA as well as the uncertainty about the actual circulating strains requires annual reformulation of seasonal vaccines to ensure strain match and to achieve sufficient protection of the population against this changing threat [23, 30, 34]. Production of seasonal influenza vaccines relies on global influenza surveillance programs and the use of strains recommended by the World Health Organization (WHO) 9 to 12 months ahead of the targeted season [35]. However, vaccine manufacturing, testing for effectiveness, approval by regulatory authorities, and distribution are slow processes [36], which in addition to the short shelf life of these vaccines [37] can render the vaccine fairly ineffective. Furthermore, complex egg adaptation and growth characteristics required for some viruses such as the HPAI H5N1 viruses [34] might further delay vaccine production. Most importantly, any mismatch between the strains selected for the vaccine and those circulating due to either inaccuracy of prediction or introduction of a completely new strain during this lengthy production period might result in reduced efficacy and could be potentially devastating [38–43]. As witnessed in the 2009 pdmH1N1 outbreak, completely new strains can unexpectedly emerge. Spread of new pandemic strains is difficult to contain because of the time required to engineer and manufacture effective vaccines and to prepare reagents required for vaccine lot release. These limitations clearly highlight the importance of developing a universal influenza vaccine.

4. The Viral Hemagglutinin

HA is a classical type I membrane glycoprotein which functions as a sialic acid binding and membrane fusion protein during virus entry into target cells [44]. X-ray crystallographic studies show the HA molecule as a homotrimer in its neutral pH form which projects from the viral envelope to form a rod-shaped structure [45]. Each monomer in this trimer is initially synthesized as a single polypeptide precursor (HA0) in infected cells, which is later cleaved by host trypsin-like proteases into two subunits, HA1 and HA2, linked by a single disulfide bond [44]. The HA1 subunit forms a membrane-distal globular head that contains the receptor-binding site (RBS) and most of the antigenic regions recognized by neutralizing Abs [46–48]. Five antigenic sites have been described in the head domain of the H1 subtype: Sa, Sb, Ca1, Ca2, and Cb. These sites are designated as A, B, C, D, and E in the H3 subtype [49, 50]. On the other hand, HA2 forms most of the stem-like structures that anchor the globular domain to the viral membrane [51].

Cleavage of precursor HA0 by host proteases is a prerequisite for virus infectivity [52] and a crucial determinant of virulence and tissue tropism [53–55]. The cleavage site is a predominant surface loop near a deep cavity in HA0 [45]. This cleavage event results in structural rearrangements in which the nonpolar N-terminus amino acids of HA2 (the fusion peptide) are repositioned to the interior of the trimer, thereby burying the ionizable residues in the cleaved HA and generating a fusion competent structure [45]. Upon acidification in the endosome, HA undergoes irreversible conformational changes that result in extrusion of the HA2 N-terminal fusion peptide domain from its buried position to the end of a long coiled-coil domain. This allows its
infection in humans and animals which raises the prospects that cross-subtype BnAbs can be induced upon vaccination or by B cells. Importantly, most of these studies have shown sorted plasmablasts and plasma cells, or hybridomas of memory naïve or immune phage display Ab libraries, Ab cloning from Group 1, Group 2, or both groups of the HA protein using highly conserved epitopes in diverse influenza viruses from isolated Abs with broad inhibitory spectrum which bind to strains within each subtype. Nonetheless, several groups have isolated Abs with broad inhibitory spectrum which bind to highly conserved epitopes in diverse influenza viruses from Group 1, Group 2, or both groups of the HA protein using naïve or immune phage display Ab libraries, Ab cloning from sorted plasmablasts and plasma cells, or hybridomas of memory B cells. Importantly, most of these studies have shown that cross-subtype BnAbs can be induced upon vaccination or infection in humans and animals which raises the prospects of HA-targeted universal influenza vaccine development.

5. Identification of Broadly Neutralizing Anti-HA Abs (BnAbs)

The HA protein represents an attractive target for vaccine development because of its important roles in the early stages of virus infection. However, the host immune system usually recognizes the bulky and highly variable-immunodominant globular head domains in the HA which shield the more conserved regions such as those in the stem part [57, 58]. In addition, memory immune response is usually elicited or recalled against these immunodominant epitopes from previously encountered strain "original antigenic sin." Therefore, development of BnAbs against diverse viral strains could be challenging as influenza A HA varies among not only the different 18 subtypes (H1–H18) which fall into two distinct phylogenetic groups (Figure 1) but also among the different strains within each subtype. Nonetheless, several groups have isolated Abs with broad inhibitory spectrum which bind to highly conserved epitopes in diverse influenza viruses from Group 1, Group 2, or both groups of the HA protein using naïve or immune phage display Ab libraries, Ab cloning from sorted plasmablasts and plasma cells, or hybridomas of memory B cells. Importantly, most of these studies have shown that cross-subtype BnAbs can be induced upon vaccination or infection in humans and animals which raises the prospects of HA-targeted universal influenza vaccine development.

5.1. HA Stem BnAbs. The first BnAb against influenza, C179 mAb, was isolated from mice immunized with H2N2 vaccine. This Ab neutralized several strains from Group 1 HA viruses including H1, H2, H5, and H9 viruses by preventing the low pH-dependent HA conformational change and the subsequent membrane fusion [59–63]. More recently, several human BnAbs were isolated including F10 and CR6261 Abs from human Ab phage display libraries prepared from nonimmune naïve and memory B cells from seasonally vaccinated individuals, respectively [64–67]. Both Abs were encoded by the germline V11–69 genes and were cross-reactive and inhibitory against several Group 1 HA viruses but not viruses from Group 2 in vitro and in vivo. F10 and CR6261 inhibited low-pH-induced HA conformational change and syncytia formation by targeting a conformational pocket-like epitope in the membrane-proximal stem of HA1/HA2 formed by the fusion peptide and the HA2 helix A [64–67]. Other human BnAbs against Group 1 HA viruses have also been isolated from B cell hybridomas from individuals vaccinated with seasonal vaccines. Abs such as FB10, FE43, and FC41 were found to recognize an acid-sensitive epitopes in the stem region and prevent the cleavage of immature HA0 into HA1 and HA2 [68]. Similarly, data on PN-SIA49 Ab suggest that its epitope is in the stem region but close to the HA globular head [69–71]. Human Abs with less cross-reactivity extent against the stem of Group 1 HA viruses were also obtained from plasmablast of pdmH1N1 infected individuals [72], bone marrow of H5N1 survivors [73, 74], and plasmablast of adults vaccinated with subunit pdmH1N1 vaccine [75] (Table 1).

While numbers are yet limited compared to Group 1 Abs, several BnAbs against Group 2 HA viruses were also isolated using hybridomas of peripheral memory B cells from individuals vaccinated with seasonal vaccine. Interestingly, CR8020 and CR8043 were obtained from the same individual but used different V₃₃ genes families (1–18 and 1–3, resp.) [76, 77]. These two BnAbs target a conserved epitope in the HA stem base of Group 2 HA viruses (H3, H7, and H10) which is distinct from those recognized by Group 1 Abs. The epitopes for both CR8020 and CR8043 overlap in the stem base β sheet and fusion peptide, but the two Abs use different approach angles with different contact residues [76, 77]. Both Abs prevented immature HA0 cleavage into HA1 and HA2 and stabilized the perfusion HA conformation [76, 77] (Table 1).

Wider range BnAbs targeting epitopes shared by both Groups 1 and 2 subtypes were also described. Fl6v3 is a good example of these Abs in which it was isolated and cloned from a single CD138⁺ plasma cell obtained from a pdmH1N1 infected individual and vaccinated with seasonal vaccine. Fl6v3 bound to all 16 HA subtypes and neutralized H1, H3, H5, and H7 viruses in vitro and in vivo. It bound to a conserved epitope in the stem similar to CR6261 and F10, using different approach by avoiding contact with nearby glycans in Group 2 viruses which extended its breadth to both groups. Interestingly, its in vivo efficacy was found to be dependent on antibody effector mechanisms [78]. Similar Abs targeting similar epitopes in both HA groups and encoded by the same germline V₃₃–30 genes were also
Table 1: Summary of anti-HA stem BnAbs.

| Ab           | Neutralization breadth | Year* | References          |
|--------------|------------------------|-------|---------------------|
| CI79         | Group 1 viruses        | 1993  | [59–63]             |
| F10          | Group 1 viruses        | 2009  | [64]                |
| CR6261       | Group 1 viruses        | 2008  | [65–67]             |
| FB110        | Group 1 viruses        | 2010  | [68]                |
| FE43         | Group 1 viruses        | 2010  | [68]                |
| FC41         | Group 1 viruses        | 2010  | [68]                |
| PN-SIA49     | Group 1 viruses        | 2009  | [69–71]             |
| 70-5B03      | Group 1 viruses        | 2011  | [72]                |
| 70-1F02      | Group 1 viruses        | 2011  | [72]                |
| 1000-3D04    | Group 1 viruses        | 2011  | [72]                |
| 1009-3B05    | Group 1 viruses        | 2011  | [72]                |
| 1009-3E06    | Group 1 viruses        | 2011  | [72]                |
| A06          | Group 1 viruses        | 2008  | [73, 74]            |
| 09-2A06      | Group 1 viruses        | 2012  | [75]                |
| 09-3A01      | Group 1 viruses        | 2012  | [75]                |
| CR8020       | Group 2 viruses        | 2011  | [76, 77]            |
| CR8043       | Group 2 viruses        | 2014  | [77]                |
| 12D1         | Group 2 viruses        | 2010  | [121]               |
| F16v3        | Group 1 and Group 2 viruses | 2011 | [78] |
| 39.29        | Group 1 and Group 2 viruses | 2013 | [80] |
| 81.39        | Group 1 and Group 2 viruses | 2013 | [80] |
| PN-SIA28     | Group 1 and Group 2 viruses | 2009 | [69, 70, 79] |
| Uni-1        | Group 1 and Group 2 viruses | 2008 | [122–125] |
| CR9114       | Influenza A and B viruses | 2012 | [81] |

*Neutralization breadth was based on in vitro neutralization and in vivo protection in cited references.

Year of first report.

CR9114 sets itself as a unique BnAb as it neutralizes not only the two groups of influenza A viruses but also the two lineages of B viruses. This unique Ab was obtained from a phage display Ab library prepared from an individual vaccinated with seasonal influenza vaccine and used germline $V_{H}^{1–69}$ genes. It bound to the F subdomain and neutralized Group 1 and Group 2 influenza A viruses in vitro and in vivo by blocking the pH-dependent conformational rearrangement required for membrane fusion similar to F16v3 Ab. Interestingly, it failed to neutralize influenza B viruses in vitro but protected mice from lethal challenges with viruses from both Victoria and Yamagata lineages [81] (Table 1).

Notably, many of the stem-targeting BnAbs were preferentially encoded by $V_{H}^{1–69}$ germline genes, showed no hemagglutination inhibition (HI) activity, and competed with CI79 mAb. They bind to a highly conserved region in the HA stem region and share the fusion peptide as a part of their epitopes. The mechanism of cross-neutralization by these Abs depends on stabilizing the HA perfusion conformation or preventing the pH-dependent HA conformational changes required for the membrane fusion step.

5.2. HA Head BnAbs. Several subtype-specific BnAbs targeting epitopes in the head domains of wide range of strains belonging to H1, H2, H3, and H5 subtypes have been isolated using several approaches (Table 2). H1-specific BnAbs such as 1F1, 2D1, 5J8, CH65, and CH67 were isolated from healthy elderly or adults, pdmH1N1 infected individuals, or people vaccinated with seasonal influenza vaccines. These Abs prevented viral attachment and sometimes viral release by recognizing conserved epitopes in the antigenic sites in the head domain encompassing or near the RBS [72, 82–89]. Several H2- or H3-specific BnAbs were also obtained from healthy volunteers and found to have HI and neutralization activity by binding to similar epitopes [90–94]. Of note, F005-126 Ab showed no HI activity and mediated its neutralization by preventing the low-pH-induced conformational change in HA similar to stem-targeting Abs, although it bound to the head domain in H3 viruses [94]. Similarly, anti-head domain BnAbs targeting conserved linear or conformational nonlinear epitopes encompassing or in close proximity to the RBS in several H5 clades have been isolated from H5N1 survivors. These H5-specific BnAbs neutralized several H5 viruses in vitro and in vivo and showed HI activity [95–97]. BnAbs targeting epitopes in the head domain of influenza B viruses only have also been found [81]. Here, CR8033 showed HI activity against viruses from Yamagata lineage and mediated its neutralization by interfering with receptor binding. On the other hand, it had no HI activity against strains from Victoria lineage and it neutralized these viruses by preventing
Table 2: Summary of anti-HA head BnAbs.

| Ab                  | Neutralization breadth* | Year* | References         |
|---------------------|-------------------------|-------|--------------------|
| 1F1                 | H1 subtype              | 2008  | [82, 83]           |
| 2D1                 | H1 subtype              | 2008  | [82, 84, 86]       |
| CH65                | H1 subtype              | 2011  | [88]               |
| CH67                | H1 subtype              | 2011  | [88, 89]           |
| 5J8                 | H1 subtype              | 2011  | [85, 87]           |
| 1009-3B06           | H1 subtype              | 2011  | [72]               |
| 1009-3F01           | H1 subtype              | 2011  | [72]               |
| 1120                | H1 subtype              | 2008  | [82, 83]           |
| 2B12                | H1 subtype              | 2008  | [82]               |
| 4D20                | H1 subtype              | 2008  | [82]               |
| 8F8                 | H2 subtype              | 2012  | [90, 91]           |
| 8M2                 | H2 subtype              | 2012  | [90, 91]           |
| FabIF1A11           | H3 subtype              | 2008  | [92]               |
| F005-126            | H3 subtype              | 2011  | [93, 94]           |
| AVFlulgG01          | H5 subtype              | 2009  | [95]               |
| AVFlulgG03          | H5 subtype              | 2009  | [95]               |
| FLA3.14             | H5 subtype              | 2007  | [96]               |
| FLD21.140           | H5 subtype              | 2007  | [96, 97]           |
| FLD20.19            | H5 subtype              | 2007  | [96]               |
| FLA5.10             | H5 subtype              | 2007  | [96, 97]           |
| FE17                | Group 1 viruses         | 2010  | [68]               |
| SI39/1              | Group 1 and Group 2 viruses | 2009 | [98, 99]     |
| C05                 | Group 1 and Group 2 viruses | 2012 | [67]               |
| 2G1                 | Group 1 and Group 2 viruses | 2012 | [90, 91]           |
| F045-092            | Group 1 and Group 2 viruses | 2011 | [93]               |
| F026-427            | Group 1 and Group 2 viruses | 2011 | [93]               |
| CR8033              | Influenza A and B viruses | 2012 | [81]               |
| CR8071              | Influenza A and B viruses | 2012 | [81]               |

* Neutralization breadth was based on in vitro neutralization and in vivo protection in cited references.

† Year of first report.

viral release from infected cells in a similar fashion to CR8071 which neutralizes both lineages by inhibiting viral release [81].

SI39/1 is a murine mAb isolated from mice immunized intranasally with H3 virus and recognizes a novel conformational epitope near the RBS. It neutralized viruses from Group 1 and Group 2 by means of avidity [98, 99]. The human C05 Ab also neutralized viruses from both groups in vitro and protected mice against lethal H1N1 and H3N2 challenges. Crystal structure data suggest that C05 prevents viral attachment through steric hindrance and cross-linking of HA on the surface of the virus via avidity similar to SI39/1 [67]. Several other BnAbs targeting sites in the HA globular head near the RBS in Group 1 and/or Group 2 viruses such as FE17 and 2G1 were also identified from vaccinated or healthy donors [68, 90, 91, 93].

Compared to stem-targeting BnAbs which block viral fusion and require Fc-IgG Fc receptors (Fcy Rs) interaction to confer protection via effector mechanisms such as antibody dependent cellular cytotoxicity (ADCC) [78, 100], most anti-head Abs neutralize viruses by inhibiting viral attachment to sialic acids receptors on target cells. Furthermore, while most subtype-specific BnAbs neutralize several strains within each subtype by targeting conserved elements in the head domain, their breadth and cross-reactivity are limited to one subtype most likely due to their interaction with highly variable residues in HA head domain. On the other hand, broader spectrum anti-HA head Abs, such as SI39/1 and C05, avoid contact with such residues. Nonetheless, isolation of these BnAbs indicates that some regions in the head domain are sufficiently conserved and exposed to induce broader protection than initially thought.

6. Induction of BnAbs

Several studies have shown that BnAbs targeting conserved HA stem or head domains can be induced upon seasonal influenza infection [67, 92], H5N1 infection [73, 95, 96], and pdmH1N1 infection [72, 78, 101–104] in humans. Several other reports have also shown that seasonal or pdmH1N1 vaccines can induce such Abs against diverse viruses [65, 68, 75, 76, 81, 88]. Interestingly, very low levels of BnAbs against
Group 1 and 2 viruses including viruses that have never been experienced in humans have been found in intravenous immunoglobulin (IVIG) and prevaccination serum samples [64]. Moreover, even though many of these BnAbs were constructed from combinatorial Ab libraries, naturally occurring BnAbs have been isolated [93]. These Abs have been shown to be long-lasting and to have high degree of somatic hypermutation suggesting their memory origin [68, 75, 102, 104]. Current immunological and technological advances allowed the generation of innovative and novel vaccine platforms to elicit heterosubtypic protection. These advances include use of adjuvants, alternative delivery vectors, routes or regimens, and novel HA-based vaccines.

6.1. Use of Adjuvants. Coadministration of adjuvants is an effective approach for inducing cross-protection. Toll-like receptors (TLRs) were proven to be highly effective in inducing potent immune response. For example, flagellin, which is a TLR-5 agonist, has been used in several studies and shown to enhance immune responses and cross-protection when used as an adjuvant in virus-like particles (VLPs) expressing influenza HA or when it is fused to HA [75, 105]. Other TLR ligands such as the TLR-3 ligand (ligand polyinosinic-polycytidylic acid, poly I:C) [106] and the licensed Adjuvant System 04 (AS04) which is comprised of TLR-4 agonist (3-O-desacyl-4-monophosphoryl lipid A, MPL) and aluminum hydroxide (Alum) [107] have also been shown to enhance heterosubtypic protection. Interestingly, a recent report has demonstrated the importance of TLR-7 in generating cross-protection upon immunization with inactivated H5N1 vaccine in mice, suggesting that the use of TLR-7 ligands can provide a way to enhance heterosubtypic protection [108]. Other adjuvants have also been shown to boost Ab response and induce anti-stem BnAbs, but further studies are clearly needed [109, 110].

Targeting HA protein to antigen presenting cells (APCs) can also represent a promising approach to enhance cross-protective Ab response. For instance, HA2 segment (residues 23–185) inserted into a detoxified adenylyl cyclase toxoid (CyaA-E5), denoted as CyaA-E5-HA2, induced potent T cell responses, broadly cross-protective HA2-specific Abs, and protected mice from lethal homologous and heterologous viruses [111]. Also, we recently showed that intranasal immunization of mice with recombinant adenovirus (rAd) expressing fusion protein consisting of codon-optimized HA2-subunit of A/California/7/2009(H1N1) virus fused to a trimerized form of CD40L completely protected mice against lethal challenges with divergent influenza A subtypes including H1N1, H3N2, and H9N2. Importantly, use of CD40L as targeting molecule and molecular adjuvant with HA2 subunit in this study elicited BnAbs capable of neutralizing 13 subtypes of influenza A viruses in vitro [112]. Thus, the use of such adjuvants or approaches can overcome the weak immunogenicity of highly conserved regions and could induce BnAbs.

6.2. Alternative Delivery Vectors, Routes, or Regimens. Recombinant replication-deficient or live-attenuated vectors (Reviewed in [113]) or DNA vaccines have been shown to be promising delivery candidates for inducing long-lasting and broad immunity against influenza. For instance, immunization with rAd or DNA vaccine expressing synthetic consensus HA protein from H1 viruses (rAd-HA1-con) [114], H7 viruses (pH7HA) [115], or H5 viruses (pCHA5) [116] induced potent Ab responses and protected mice against diverse lethal subtype-specific challenges, suggesting that consensus HA proteins can at least provide subtype-specific immunity. Other platforms such as VLP have also been used and shown to be effective in inducing broad immunity [105, 117].

Several studies have also shown induction of heterosubtypic immunity by alternative immunization routes or regimens. Intranasal immunization with monovalent replication-deficient delNS1-HINI influenza virus vaccine elicited significant levels of circulatory IgG and local IgA in humans. Importantly, mucosal Abs showed heterosubtypic neutralization against H3N2 and H5N1 viruses [118]. Oral vaccination of mice with inactivated whole influenza virus (A/PR8/34) induced high levels of mucosal and circulatory heterosubtypic IgG and IgA Abs with HI activity. This response protected mice completely against homologous or heterologous challenges and partially against heterosubtypic virus [119]. Prime-boost regimen with DNA vaccine expressing H1 and seasonal vaccine or rAd expressing H1 induced anti-stem BnAbs and conferred complete protection against divergent HINI viruses in mice, ferrets, and nonhuman primates [120].

6.3. Novel HA Vaccines. Several novel vaccines or immunogens based on the isolation of BnAbs, structural data obtained from BnAbs studies, or the identification of highly conserved regions have been developed and examined. While most of these novel vaccines provided limited heterosubtypic protection against lethal influenza challenge, they represent an important step towards universal influenza vaccine development.

6.3.1. Peptide-Based Vaccines. Immunization of mice with synthetic peptide (amino acids 76–130) from the long α-helix of H3 HA2 subunit (strain A/HK/68 HA) fused to keyhole limpet hemocyanin (KLH) not only improved mouse survival and reduced viral load against homologous challenge but also provided partial protection against heterosubtypic viruses from Group 1 HA [121]. Use of VLP expressing 180 copies of the 20-residue A-helix from HA2 in Group 1 viruses which is a major part of the epitope recognized by CR6261 and F10 BnAbs induced cross-reactive Abs against Group 1 but not Group 2 viruses. However, these VLPs failed to protect mice and the elicited Abs showed no neutralization activity in vitro [117]. Through comprehensive bioinformatics analysis of all publicly available HA sequences, we recently showed that the N-terminal 14 amino acids of the fusion peptide (GLFGAIAGFIEGGW) represent the most conserved peptide in all 16 subtypes of influenza A and the two genetic lineages of influenza B viruses [122–125]. Immunization of rabbits with this peptide linked to KLH generated universal anti-influenza Abs (Uni-1 Abs) that are cross-reactive to virtually all influenza HA subtypes with high specificity [122, 123]. Importantly, Uni-Ab cross-neutralized multiple subtypes of
influenza A virus by inhibiting the pH-dependent viral and cellular membranes fusion [124]. Interestingly, at least two similar neutralizing Abs targeting the fusion peptide were generated from immunization of mice with recombinant H5N1 HA0 [126] or memory B cells of pdmH1N1 infected person [127], suggesting that this highly conserved linker peptide is at least partially exposed to induce Abs and is accessible for binding which warrants further investigation.

6.3.2. Conserved HA Regions-Focused Vaccines. Despite the efficacy of anti-head BnAbs, these Abs are usually more efficient in selecting escape mutants in vitro and in vivo compared to anti-stem Abs which target highly conserved epitopes across divergent influenza subtypes [68, 128, 129]. Furthermore, isolation of anti-stem BnAbs from pdmH1N1 infected or vaccinated individuals suggest that vaccines containing HA head domains with substantial difference compared to seasonal strains can skew the immune response and boost HA stem Abs by stimulating the rare memory B cells targeting the highly conserved sequences in the HA protein [101–104]. Therefore, it was proposed that vaccine aimed at eliciting stem BnAbs could be a good way to provide a long-lasting universal protection against influenza. Several approaches including the use of “headless” HA protein, HA in the neutral-pH conformation, masking of highly variable-immunodominant regions, or chimeric HA proteins have been used.

For example, headless HA protein lacking the globular domain from H1N1, H2N2, or H3N2 viruses and expressed as recombinant protein or by VLPs was developed and investigated. However, while it elicited anti-HA stalk Abs, its protection was restricted to viruses whose HAs are in the same phylogenetic group as that of the immunogen [58, 130]. Similar headless H5 recombinant vaccine produced in baculovirus has been developed and is being investigated [131]. In another approach, immunization of mice with recombinant HA2 subunit with regions (7–46) and (290–321) from HA1 of H3N2 virus expressed in its neutral pH-conformation protected mice against homologous challenge only and elicited neutralizing Abs against other strains within the same subtype [132].

Other interesting approaches such as glycan masking and chimeric HA protein have been tested to skew immune response towards conserved HA regions. For instance, Eggink et al. have shown that intramuscular immunization of mice with recombinant hyperglycosylated HA protein, glycans introduced in 7 N-linked glycosylation sites at the antigenic sites in the head domain to shield these immunodominant sites, adjuvanted with poly(I:C), can skew Ab response towards the stem region by up to 9 folds after 3 immunizations, enhance heterologous protection, and elicit heterologous and heterosubtypic Ab response [133]. Similarly, glycan masking of H5NI HA protein has resulted in induction of BnAbs similar to CR6162 and showed cross-clade protection against heterologous H5NI viruses [134]. Other groups have also shown that prime-boost immunization with vaccines expressing chimeric HA proteins comprised of the globular head domain of unrelated HA subtypes with the stalk domain of particular subtypes (such as cH4/3, cH5/3 or cH7/1 HAs) can skew the Ab response towards the stem, induce highly cross-reactive anti-stem BnAbs to heterologous HAs, and confer broad cross-protection against various viruses [135–137].

6.3.3. Polyvalent HA Vaccines. Vaccines expressing multivalent or combination of HA have also been investigated to evaluate their abilities to confer heterologous and heterosubtypic protection. Trivalent recombinant H5 vaccine with oil-in-water emulsion adjuvant SP01 provided complete cross-protection against HPAI H5NI virus in mice compared to monovalent vaccine [138]. Similar results were also observed upon trivalent or tricalde H5 DNA immunization against several heterologous H5 clades and subclades [139–141]. However, the breadth was dependent on the choice of the HA in the vaccine [139]. Immunization with rAd vectors expressing combination of HA from H1, H5, H7, and H9 induced high levels of stem-specific neutralizing Abs and conferred protection against virus replication following challenge with antigenically distinct viruses from these subtypes [142]. Furthermore, recombinant modified vaccinia virus Ankara (MVA) vector expressing HA from H5NI A/Vietnam/1203/04, A/Indonesia/669/06, and A/Anhui/01/05 viruses (MVAtor-tri-HA vector) elicited potent cross-neutralizing protection in mice against H5NI challenge from divergent clade. Importantly, it induced cross-clade neutralizing immunity against twenty different H5NI strains from six clades in guinea pigs [143].

7. Conclusion and Future Directions

One of the major inherent drawbacks of current influenza vaccines is the need for annual reformulation to antigenically match circulating strains. This is mostly due to the inability of these vaccines to induce cross-protective immune responses against the highly diverse influenza viruses. Isolation of arsenal of anti-HA BnAbs and the elucidation of the structural, molecular, and biological basis of their neutralizing and protective abilities helped in the development of several HA-based universal vaccine candidates. While the efficacy of many of the aforementioned novel approaches based on rational vaccine design and the use of effective adjuvants and alternative immunization regimens or routes seem to be limited to certain influenza subtypes or groups, they clearly show an improvement over the current annual vaccination strategies, demonstrate a wide range of options available for more exploration, and represent a promising step towards the development of broadly protective influenza vaccine. Nonetheless, development of an ideal HA-based universal influenza vaccine which could provide life-long protection against all influenza viruses clearly necessitates more preclinical and clinical studies to elucidate the underlying molecular mechanisms involved in eliciting such cross-protective immunity and more importantly to eliminate any safety concerns associated with these novel approaches.

Conflict of Interests

No conflict of interests is declared.
Acknowledgment

This work was funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia, under Grant no. (1434/140/483).

References

[1] A. E. Fiore, D. K. Shay, K. Broder et al., "Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)," Morbidity and Mortality Weekly Report, vol. 58, pp. 1–52, 2009.
[2] World Health Organization, "Influenza," Fact sheet no. 211, 2003.
[3] S. Tong, Y. Li, P. Rivailer et al., "A distinct lineage of influenza A virus from bats," Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 11, pp. 4269–4274, 2012.
[4] S. Tong, X. Zhu, Y. Li et al., "New world bats harbor diverse influenza a viruses," PLoS Pathogens, vol. 9, Article ID e1003657, 2013.
[5] P. A. Rota, T. R. Wallis, M. W. Harmon, J. S. Rota, A. P. Kendall, and K. Neron, "Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983," Virology, vol. 175, no. 1, pp. 59–68, 1990.
[6] M. C. Zambon, "Epidemiology and pathogenesis of influenza," Journal of Antimicrobial Chemotherapy, vol. 44, pp. 3–9, 1999.
[7] I. Capua and D. J. Alexander, "Human health implications of avian influenza viruses and paramyxoviruses," European Journal of Clinical Microbiology and Infectious Diseases, vol. 23, no. 1, pp. 1–6, 2004.
[8] R. G. Webster, W. J. Bean, O. T. Gorman, T. M. Chambers, and Y. Kawaoka, "Evolution and ecology of influenza a viruses," Microbiological Reviews, vol. 56, no. 1, pp. 152–179, 1992.
[9] P. Palese, "Influenza: old and new threats," Nature Medicine, vol. 10, pp. S82–S87, 2004.
[10] S. Ludwig, L. Stitz, O. Planz, H. Van, W. M. Fitch, and C. Scholtissek, "European swine virus as a possible source for the next influenza pandemic?" Virology, vol. 212, no. 2, pp. 555–561, 1995.
[11] K. M. Sturm-Ramirez, T. Ellis, B. Bousfield et al., "Reemerging H5N1 influenza viruses in Hong Kong in 2002 are highly pathogenic to ducks," Journal of Virology, vol. 78, no. 9, pp. 4982–4901, 2004.
[12] A. C.-C. Shih, T.-C. Hsiao, M.-S. Ho, and W.-H. Li, "Simultaneous amino acid substitutions at antigenic sites drive influenza A hemagglutinin evolution," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 15, pp. 6283–6288, 2007.
[13] D. A. Steinhauer and J. J. Skehel, "Genetics of influenza viruses," Annual Review of Genetics, vol. 36, pp. 305–332, 2002.
[14] C. Scholtissek, W. Rohde, E. Harms, R. Rott, M. Orlich, and C. B. Boschek, "A possible partial heterozygote of an influenza a virus," Virology, vol. 89, no. 2, pp. 506–516, 1978.
[15] Y. Kawaoka, S. Krauss, and R. G. Webster, "Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics," Journal of Virology, vol. 63, no. 11, pp. 4603–4608, 1968.
[16] S. Ludwig, O. Planz, S. Pleschka, and T. Wolff, "Influenza-virus-induced signaling cascades: targets for antiviral therapy?" Trends in Molecular Medicine, vol. 9, no. 2, pp. 46–52, 2003.
[17] R. B. Belshe, "Implications of the emergence of a novel H1 influenza virus," The New England Journal of Medicine, vol. 360, no. 25, pp. 2667–2668, 2009.
[18] R. J. Garten, C. T. Davis, C. A. Russell et al., "Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans," Science, vol. 325, no. 5937, pp. 197–201, 2009.
[19] K. Subbarao, A. Klimov, J. Katz et al., "Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness," Science, vol. 279, no. 5349, pp. 393–396, 1998.
[20] Y. P. Lin, M. Shaw, V. Gregory et al., "Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 17, pp. 9654–9658, 2000.
[21] R. A. M. Fouchier, P. M. Schneeberger, F. W. Rozendaal et al., "Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 5, pp. 1356–1361, 2004.
[22] Centre for Disease Control and Prevention (CDC), CDC: Seasonal Influenza (Flu), 2014, http://www.cdc.gov/flu/avianflu/h7n9-virus.htm.
[23] P. Palese, "Making better influenza virus vaccines?" Emerging Infectious Diseases, vol. 12, no. 1, pp. 61–65, 2006.
[24] R. Bergen, S. Black, H. Shinefield et al., "Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents," Pediatric Infectious Disease Journal, vol. 23, no. 2, pp. 138–144, 2004.
[25] R. B. Belshe, K. L. Nichol, S. B. Black et al., "Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5–49 years," Clinical Infectious Diseases, vol. 39, no. 7, pp. 920–927, 2004.
[26] US Food and Drug Administration (USFDA), "2012 Approval Letter-FluMist," http://www.fda.gov/BiologicsBloodVaccines/ApprovedProducts/ucm313179.htm.
[27] European Center for Disease Prevention and Control (ECDC), http://www.ecdc.europa.eu/en/healthtopics/seasonal_influenza/vaccines/Pages/influenza_vaccination.aspx.
[28] C. S. Ambrose and M. J. Levin, "The rationale for quadrivalent influenza vaccines," Human Vaccines & Immunotherapeutics, vol. 8, no. 1, pp. 81–88, 2012.
[29] S. L. Epstein, "Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature," The Journal of Infectious Diseases, vol. 193, no. 1, pp. 49–53, 2006.
[30] W. Gerhard, K. Mozdzanowska, and D. Zharikova, "Prospects for universal influenza virus vaccine," Emerging Infectious Diseases, vol. 12, no. 4, pp. 569–574, 2006.
[31] R. B. Belshe, W. C. Gruber, P. M. Mendelman et al., "Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine," Journal of Infectious Diseases, vol. 181, no. 3, pp. 1133–1137, 2000.
[32] C. S. Ambrose, M. J. Levin, and R. B. Belshe, "The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults," Influenza and other Respiratory Viruses, vol. 5, no. 2, pp. 67–75, 2011.
[33] R. B. Belshe, P. M. Mendelman, J. Treanor et al., "The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children," The New England Journal of Medicine, vol. 338, no. 20, pp. 1405–1412, 1998.
J. M. Wood, “Selection of influenza vaccine strains and developing pandemic vaccines,” *Vaccine*, vol. 20, supplement 5, pp. B40–B44, 2002.

F. Carrat and A. Flahault, “Influenza vaccine: the challenge of antigenic drift,” *Vaccine*, vol. 25, pp. 6652–6682, 2007.

R. J. Drape, M. D. Macklin, L. J. Barr, S. Jones, J. R. Haynes, and H. J. Dean, “Epidermal DNA vaccine for influenza is immunogenic in humans,” *Vaccine*, vol. 24, no. 21, pp. 4475–4481, 2006.

D. S. Fedson, “Pandemic influenza and the global vaccine supply,” *Clinical Infectious Diseases*, vol. 36, no. 12, pp. 1552–1561, 2003.

C. Buxton Bridges, W. W. Thompson, M. I. Meltzer et al., “Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial,” *The Journal of the American Medical Association*, vol. 284, no. 13, pp. 1655–1663, 2000.

M. de Filette, W. M. Jou, A. Birkett et al., “Universal influenza A vaccine: optimization of M2-based constructs,” *Virology*, vol. 337, no. 1, pp. 149–161, 2005.

M. Aymard, M. Valette, B. Lina, and D. Thouvenot, “Surveillance and impact of influenza in Europe,” *Vaccine*, vol. 17, supplement 1, pp. S30–S41, 1999.

A. Klimov, L. Simonsen, K. Fukuda, and N. Cox, “Surveillance and impact of influenza in the United States,” *Vaccine*, vol. 17, supplement 1, pp. S42–S46, 1999.

J. C. de Jong, W. E. P. Beyer, A. M. Palache, G. F. Rimmelewaan, and A. D. Osterhaus, “Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly,” *Journal of Medical Virology*, vol. 61, no. 1, pp. 94–99, 2000.

K. Yohannes, P. Roche, A. Hampson, M. Miller, and J. Spencer, “Annual report of the National Influenza Surveillance Scheme, 2003,” *Communicable Diseases Intelligence*, vol. 28, no. 2, pp. 160–168, 2004.

J. J. Skehel and D. C. Wiley, “Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin,” *Annual Review of Biochemistry*, vol. 69, pp. 531–569, 2000.

K. J. Cross, W. A. Langley, R. J. Russell, J. J. Skehel, and D. A. Steinhauer, “Composition and functions of the influenza fusion peptide,” *Protein and Peptide Letters*, vol. 16, no. 7, pp. 766–778, 2009.

R. G. Webster and W. G. Laver, “Determination of the number of nonoverlapping antigenic areas on Hong Kong (H3N2) influenza virus hemagglutinin with monoclonal antibodies and the selection of variants with potential epidemiological significance,” *Virology*, vol. 104, no. 1, pp. 139–148, 1980.

W. Gerhard, J. Yewdell, M. E. Frankel, and R. Webster, “Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies,” *Nature*, vol. 290, no. 5808, pp. 713–717, 1981.

D. C. Wiley and J. J. Skehel, “The structure and function of the hemagglutinin membrane glycoprotein of influenza virus,” *Annual Review of Biochemistry*, vol. 56, pp. 365–394, 1987.

A. J. Caton, G. G. Brownlee, J. W. Yewdell, and W. Gerhard, “The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype),” *Cell*, vol. 31, no. 2, pp. 417–427, 1982.

D. C. Wiley, I. A. Wilson, and J. J. Skehel, “Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation,” *Nature*, vol. 289, pp. 373–378, 1981.

J. Chen, S. A. Wharton, W. Weissenhorn et al., “A soluble domain of the membrane-anchoring chain of influenza virus hemagglutinin (HA) folds in *Escherichia coli* into the low-pH-induced conformation,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 92, no. 26, pp. 12205–12209, 1995.

S. G. Lazarowitz and P. W. Choppin, “Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide,” *Virology*, vol. 68, no. 2, pp. 440–454, 1975.

T. Horimoto and Y. Kawaoka, “Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus,” *Journal of Virology*, vol. 68, no. 5, pp. 3120–3128, 1994.

D. A. Steinhauer, “Role of hemagglutinin cleavage for the pathogenicity of influenza virus,” *Virology*, vol. 258, no. 1, pp. 1–20, 1999.

S. Bertram, I. Glowacka, I. Steffen, A. Kühl, and S. Pöhlmann, “Novel insights into proteolytic cleavage of influenza virus hemagglutinin,” *Reviews in Medical Virology*, vol. 20, no. 5, pp. 298–310, 2010.

M.-J. Gething, R. W. Dombs, D. York, and J. White, “Studies on the mechanism of membrane fusion: site-specific mutagenesis of the hemagglutinin of influenza virus,” *The Journal of Cell Biology*, vol. 102, no. 1, pp. 11–23, 1986.

G. J. Nabel and A. S. Fauci, “Induction ofunaltered immunity: prospects for a broadly protective universal influenza vaccine,” *Nature Medicine*, vol. 16, no. 12, pp. 1389–1391, 2010.

J. Steel, A. C. Lowen, T. T. Wang, M. Yondola, and Q. Gao, “Influenza virus vaccine based on the conserved hemagglutinin stalk domain,” *mBio*, vol. 1, no. 1, Article ID e00018-10, 2010.

Y. Okuno, Y. Isegawa, F. Sasao, and S. Ueda, “A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains,” *Journal of Virology*, vol. 67, no. 5, pp. 2552–2558, 1993.

Y. A. Smirnov, A. S. Lipatov, A. K. Gitelman, and A. D. M. E. Osterhaus, “Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian HSN2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem region,” *Archives of Virology*, vol. 145, no. 8, pp. 1733–1741, 2000.

S. Sakabe, K. Iwatsuki-Horimoto, T. Horimoto et al., “A cross-reactive neutralizing monoclonal antibody protects mice from HSN1 and pandemic (H1N1) 2009 virus infection,” *Antiviral Research*, vol. 88, no. 3, pp. 249–255, 2010.

C. Dreyfus, D. C. Ekiert, and I. A. Wilson, “Structure of a classical broadly neutralizing stem antibody in complex with a pandemic H2 influenza virus hemagglutinin,” *Journal of Virology*, vol. 87, no. 12, pp. 7149–7154, 2013.

M. Throsby, E. van den Brink, M. Jongeneelen et al., “Hetero-subtypic neutralizing monoclonal antibodies cross-protective
against H5N1 and H1N1 recovered from human IgM memory B cells,” *PLoS ONE*, vol. 3, no. 12, Article ID e3942, 2008.

[66] D. C. Ekiert, G. Bhabha, M.-A. Elsliger et al., “Antibody recognition of a highly conserved influenza virus epitope,” *Science*, vol. 324, no. 5924, pp. 246–251, 2009.

[67] D. C. Ekiert, A. K. Kashyap, J. Steele et al., “Cross-neutralization of influenza A viruses mediated by a single antibody loop,” *Nature*, vol. 489, no. 7417, pp. 526–532, 2012.

[68] D. Corti, A. L. Suguitan Jr., D. Pinna et al., “Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine,” *The Journal of Clinical Investigation*, vol. 120, no. 5, pp. 1663–1673, 2010.

[69] R. Burioni, F. Canducci, N. Mancini et al., “Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV),” *New Microbiologica*, vol. 32, no. 4, pp. 319–324, 2009.

[70] R. Burioni, F. Canducci, N. Mancini et al., “Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV),” *Virology*, vol. 399, no. 1, pp. 144–152, 2010.

[71] D. de Marco, N. Clementi, N. Mancini et al., “A non-VHH-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses,” *PLoS ONE*, vol. 7, no. 4, Article ID e34415, 2012.

[72] J. Wrammert, D. Koutsonanos, G. M. Li et al., “Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection,” *Journal of Experimental Medicine*, vol. 208, no. 1, pp. 181–193, 2011.

[73] A. K. Kashyap, J. Steel, A. F. Oner et al., “Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 16, pp. 5986–5991, 2008.

[74] A. K. Kashyap, J. Steel, A. Rubrum et al., “Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries,” *PLoS Pathogens*, vol. 6, no. 7, Article ID e1000990, 7 pages, 2010.

[75] G.-M. Li, C. Chiu, J. Wrammert et al., “Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 109, no. 23, pp. 9047–9052, 2012.

[76] D. C. Ekiert, R. H. E. Friesen, G. Bhabha et al., “A highly conserved neutralizing epitope on group 2 influenza A viruses,” *Science*, vol. 333, no. 6044, pp. 843–850, 2011.

[77] R. H. Friesen, P. S. Lee, E. J. Stoop et al., “A common solution to group 2 influenza virus neutralization,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 110, no. 1, pp. 445–450, 2014.

[78] D. Corti, J. Voss, S. J. Gamblin et al., “A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins,” *Science*, vol. 333, no. 6044, pp. 850–856, 2011.

[79] N. Clementi, D. de Marco, N. Mancini et al., “A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes,” *PLoS ONE*, vol. 6, no. 12, Article ID e28001, 2011.

[80] G. Nakamura, N. Chai, S. Park et al., “An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies,” *Cell Host and Microbe*, vol. 14, no. 1, pp. 93–103, 2013.

[81] C. Dreyfus, N. S. Laursen, T. Kwaks et al., “Highly conserved protective epitopes on influenza B viruses,” *Science*, vol. 337, no. 6100, pp. 1343–1348, 2012.

[82] X. Yu, T. Tsibane, P. A. McGraw et al., “Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors,” *Nature*, vol. 455, no. 7212, pp. 532–536, 2008.

[83] T. Tsibane, D. C. Ekiert, J. C. Krause et al., “Influenza human monoclonal antibody IFL interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses,” *PLoS Pathogens*, vol. 8, no. 12, Article ID e1003067, 2012.

[84] J. C. Krause, D. C. Ekiert, T. M. Tumpey, P. B. Smith, I. A. Wilson, and J. E. Crowe, “An insertion mutation that distorts antibody binding site architecture enhances function of a human antibody,” *mBio*, vol. 2, no. 1, 2011.

[85] J. C. Krause, T. Tsibane, T. M. Tumpey, C. J. Huffman, C. F. Basler, and J. E. Crowe Jr., “A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza HI1N1 virus hemagglutinin,” *Journal of Virology*, vol. 85, no. 20, pp. 10905–10908, 2011.

[86] R. Xu, D. C. Ekiert, J. C. Krause, R. Hai, J. E. Crowe Jr., and I. A. Wilson, “Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus,” *Science*, vol. 328, no. 5976, pp. 357–360, 2010.

[87] M. Hong, P. S. Lee, R. M. B. Hoffman et al., “Antibody recognition of the pandemic H1N1 influenza virus hemagglutinin receptor binding site,” *Journal of Virology*, vol. 87, no. 22, pp. 12471–12480, 2013.

[88] J. R. R. Whittle, R. Zhang, S. Khurana et al., “Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 34, pp. 14216–14221, 2011.

[89] A. G. Schmidt, H. Xu, A. R. Khan et al., “Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 110, no. 1, pp. 264–269, 2013.

[90] J. C. Krause, T. Tsibane, T. M. Tumpey et al., “Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses,” *Journal of Virology*, vol. 86, no. 11, pp. 6334–6340, 2012.

[91] R. Xu, J. C. Krause, R. Mcbride, J. C. Paulson, J. E. Crowe Jr., and I. A. Wilson, “A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin,” *Nature Structural and Molecular Biology*, vol. 20, no. 3, pp. 363–370, 2013.

[92] T. Shibuya, T. Yamashiro, Y. Masaike, M. Ohuchi, G.-I. Uechi, and A. Nishizono, “Identification of a human monoclonal Fab with neutralizing activity against H3N2 influenza A strain from a newly constructed human Fab library,” *Microbiology & Immunology*, vol. 52, no. 3, pp. 162–170, 2008.

[93] N. Ohshima, Y. Iba, R. Kubota-Koketsu, Y. Asano, Y. Okuno, and Y. Kurosawa, “Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5,” *Journal of Virology*, vol. 85, no. 21, pp. 11048–11057, 2011.

[94] Y. Iba, Y. Fujii, N. Ohshima et al., “Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses,” *Journal of Virology*, vol. 88, no. 13, pp. 7130–7144, 2014.

[95] L. Sun, X. Lu, C. Li et al., “Generation, characterization and epitope mapping of two neutralizing and protective human
recombinant antibodies against influenza A H5N1 viruses,” PLoS ONE, vol. 4, no. 5, Article ID e5476, 2009.

[96] C. P. Simmons, N. L. Bernasoni, A. L. Suguitan Jr. et al., “Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza,” PLoS Medicine, vol. 4, no. 5, article e178, 2007.

[97] S. Khurana, A. L. Suguitan Jr, Y. Rivera et al., “Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets,” PLoS Medicine, vol. 6, no. 4, Article ID e1000494, 2009.

[98] R. Yoshida, M. Igarashi, H. Ozaki et al., “Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses,” PLoS Pathogens, vol. 5, no. 3, Article ID e1000350, 2009.

[99] P. S. Lee, R. Yoshida, D. C. Ekiert et al., “Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 42, pp. 17040–17045, 2012.

[100] D. J. Dilillo, G. S. Tan, P. Palese, and J. V. Ravetch, “Broadly neutralizing hemagglutinin stalk–specific antibodies require FcyRI interactions for protection against influenza virus in vivo,” Nature Medicine, vol. 20, pp. 143–151, 2014.

[101] N. Pica, R. Hai, F. Krammer et al., “Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 7, pp. 2573–2578, 2012.

[102] C. A. Thomson, Y. Wang, L. M. Jackson et al., “Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem,” Frontiers in Immunology, vol. 3, article 87, 2012.

[103] M. S. Miller, T. Tsibane, F. Krammer et al., “1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans,” Journal of Infectious Diseases, vol. 207, no. 1, pp. 98–105, 2013.

[104] X.-S. He, S. Sasaki, J. Baer et al., “Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza,” PLoS Medicine, vol. 4, no. 5, article e178, 2007.

[105] S. Khurana, A. L. Suguitan Jr, Y. Rivera et al., “Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets,” PLoS Medicine, vol. 6, no. 4, Article ID e1000494, 2009.

[106] R. Yoshida, M. Igarashi, H. Ozaki et al., “Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses,” PLoS Pathogens, vol. 5, no. 3, Article ID e1000350, 2009.

[107] P. S. Lee, R. Yoshida, D. C. Ekiert et al., “Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 42, pp. 17040–17045, 2012.

[108] D. J. Dilillo, G. S. Tan, P. Palese, and J. V. Ravetch, “Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγRI interactions for protection against influenza virus in vivo,” Nature Medicine, vol. 20, pp. 143–151, 2014.

[109] N. Pica, R. Hai, F. Krammer et al., “Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 7, pp. 2573–2578, 2012.

[110] C. A. Thomson, Y. Wang, L. M. Jackson et al., “Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem,” Frontiers in Immunology, vol. 3, article 87, 2012.

[111] M. S. Miller, T. Tsibane, F. Krammer et al., “1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans,” Journal of Infectious Diseases, vol. 207, no. 1, pp. 98–105, 2013.

[112] X.-S. He, S. Sasaki, J. Baer et al., “Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza,” PLoS Medicine, vol. 4, no. 5, article e178, 2007.

[113] S. Khurana, A. L. Suguitan Jr, Y. Rivera et al., “Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets,” PLoS Medicine, vol. 6, no. 4, Article ID e1000494, 2009.

[114] R. Yoshida, M. Igarashi, H. Ozaki et al., “Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses,” PLoS Pathogens, vol. 5, no. 3, Article ID e1000350, 2009.

[115] P. S. Lee, R. Yoshida, D. C. Ekiert et al., “Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 42, pp. 17040–17045, 2012.

[116] D. J. Dilillo, G. S. Tan, P. Palese, and J. V. Ravetch, “Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγRI interactions for protection against influenza virus in vivo,” Nature Medicine, vol. 20, pp. 143–151, 2014.

[117] N. Pica, R. Hai, F. Krammer et al., “Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 7, pp. 2573–2578, 2012.

[118] C. A. Thomson, Y. Wang, L. M. Jackson et al., “Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem,” Frontiers in Immunology, vol. 3, article 87, 2012.

[119] M. S. Miller, T. Tsibane, F. Krammer et al., “1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans,” Journal of Infectious Diseases, vol. 207, no. 1, pp. 98–105, 2013.

[120] X.-S. He, S. Sasaki, J. Baer et al., “Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza,” PLoS Medicine, vol. 4, no. 5, article e178, 2007.

[121] S. Khurana, A. L. Suguitan Jr, Y. Rivera et al., “Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets,” PLoS Medicine, vol. 6, no. 4, Article ID e1000494, 2009.

[122] R. Yoshida, M. Igarashi, H. Ozaki et al., “Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses,” PLoS Pathogens, vol. 5, no. 3, Article ID e1000350, 2009.

[123] P. S. Lee, R. Yoshida, D. C. Ekiert et al., “Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 42, pp. 17040–17045, 2012.

[124] D. J. Dilillo, G. S. Tan, P. Palese, and J. V. Ravetch, “Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγRI interactions for protection against influenza virus in vivo,” Nature Medicine, vol. 20, pp. 143–151, 2014.

[125] N. Pica, R. Hai, F. Krammer et al., “Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 7, pp. 2573–2578, 2012.

[126] C. A. Thomson, Y. Wang, L. M. Jackson et al., “Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem,” Frontiers in Immunology, vol. 3, article 87, 2012.

[127] M. S. Miller, T. Tsibane, F. Krammer et al., “1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans,” Journal of Infectious Diseases, vol. 207, no. 1, pp. 98–105, 2013.
[125] C. Gravel, C. Li, J. Wang et al., “Quantitative analyses of all influenza type A viral hemagglutinins and neuraminidases using universal antibodies in simple slot blot assays,” *Journal of Visualized Experiments*, vol. 4, no. 50, article 2784, 2011.

[126] N. Prabhu, M. Prabakaran, H.-T. Ho et al., “Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection,” *Journal of Virology*, vol. 83, no. 6, pp. 2553–2562, 2009.

[127] W. Hu, A. Chen, Y. Miao et al., “Fully human broadly neutralizing monoclonal antibodies against influenza A viruses generated from the memory B cells of a 2009 pandemic H1N1 influenza vaccine recipient,” *Virology*, vol. 435, no. 2, pp. 320–328, 2013.

[128] E. Tsuchiya, K. Sugawara, S. Hongo et al., “Antigenic structure of the haemagglutinin of human influenza A/H2N2 virus,” *Journal of General Virology*, vol. 82, no. 10, pp. 2475–2484, 2001.

[129] S. E. Hensley, S. R. Das, A. L. Bailey et al., “Hemagglutinin receptor binding avidity drives influenza virus antigenic drift,” *Science*, vol. 326, no. 5953, pp. 734–736, 2009.

[130] H. Sagawa, A. Ohshima, I. Kato, Y. Okuno, and Y. Isegawa, “The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region,” *Journal of General Virology*, vol. 77, no. 7, pp. 1483–1487, 1996.

[131] K. Uranowska, J. Tyborowska, A. Jurek, B. Szewczyk, and B. Gromadzka, “Hemagglutinin stalk domain from H5N1 strain as a potentially universal antigen,” *Acta Biochimica Polonica*, vol. 61, no. 3, pp. 541–550, 2014.

[132] G. Bommakanti, M. P. Citron, R. W. Hepler et al., “Design of an HA2-based *Escherichia coli* expressed influenza immunogen that protects mice from pathogenic challenge,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 31, pp. 13701–13706, 2010.

[133] D. Eggink, P. H. Goff, and P. Palese, “Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain,” *Journal of Virology*, vol. 88, no. 1, pp. 699–704, 2014.

[134] S.-C. Lin, W.-C. Liu, J.-T. Jan, and S.-C. Wu, “Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibody responses against H5N1 avian influenza viruses,” *PLoS ONE*, vol. 9, no. 3, Article ID e92822, 2014.

[135] I. Margine, F. Krammer, R. Hai et al., “Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses,” *Journal of Virology*, vol. 87, no. 19, pp. 10435–10446, 2013.

[136] F. Krammer, N. Pica, R. Hai, I. Margine, and P. Palesea, “Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies,” *Journal of Virology*, vol. 87, no. 12, pp. 6542–6550, 2013.

[137] F. Krammer, R. Hai, M. Yondola et al., “Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets,” *Journal of Virology*, vol. 88, no. 6, pp. 3432–3442, 2014.

[138] F. Zhou, G. Wang, P. Buchy et al., “A triclad DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza virus H5N1,” *Journal of Virology*, vol. 86, no. 12, pp. 6970–6978, 2012.

[139] S. Wang, A. Hackett, N. Jia et al., “Polyvalent DNA vaccines expressing HA antigens of H5N1 influenza viruses with an optimized leader sequence elicit cross-protective antibody responses,” *PLoS ONE*, vol. 6, no. 12, Article ID e28757, 2011.

[140] S. V. Vemula, Y. S. Ahí, A. M. Swaim et al., “Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness,” *PLoS ONE*, vol. 8, no. 4, Article ID e62496, 2013.

[141] M. Prabakaran, S. Leyrer, F. He et al., “Progress toward a universal H5N1 vaccine: a recombinant modified vaccinia virus Ankara-expressing trivalent hemagglutinin vaccine,” *PLoS ONE*, vol. 9, no. 9, Article ID e107316, 2014.